About Us

Leveraging 60 years in polymer science and production technologies through our parent company, ARx, LLC., improves the outcomes for patients over traditional drug delivery systems, as a global leader in the development and manufacture of specialty pharmaceutical drug products, including oral and mucosal thin films and transdermal patches. We partner with both generic and branded drug companies to launch FDA approved prescription drug products that offer tailored drug usage and delivery, positive patient experiences, and market differentiation, while priding ourselves on being a true partner.

We partner with our customers from product ideation to commercial drug manufacturing. This includes pre-formulation, drug development and formulation, in-vitro permeation testing, analytical method development & validation, clinical unit production, process development, registration production, CMC filing support, and product validation. The ARx team leverages our foundation knowledge in dissolvable thin films and transdermal patches to ensure success at each step of the process.

ARx approaches each project in a flexible manner, with the ability to meet individual project needs and timelines. The team follows five core guiding principles:

• To be the best there is in the heart of our business.
• To have a work environment that treats everyone with respect and actively fosters both teamwork and individual development.
• To be the most effective company in our field at partnering with our customers in developing and producing specialized products.
• To have profitable growth so that we can continuously improve and increase our capabilities.
• To talk straight and do what we say we are going to do.

ARx, LLC., was founded in 2005, as a wholly owned cGMP subsidiary of Adhesives Research Inc. Recognizing the potential for soluble thin films to deliver active pharmaceutical ingredients, ARx became a global leader of the dosage form with the launch of the first over-the-counter pharmaceutical products for systemic drug delivery and has been a commercial drug manufacturer for over 15 years, with multiple FDA approved products. Since the technology first debuted, the thin film dosage form has expanded to include buccal and sublingual delivery applications and ARx has shifted its focus to prescription applications in both the branded and generic drug markets.

ARx is also a market leader in transdermal patches. Through Adhesives Research, ARx is able to leverage over 60 years of drug formulation and coating expertise, as well as 30 years’ experience in the development and manufacture of adhesive formulations for the transdermal patch industry. The relationships formed over the years have provided us with a unique advantage and deep understanding of the drug delivery systems and market needs.

Established in 1961, the humble beginnings of Adhesives Research originated in a converted garage to develop and supply specialty adhesive-coated materials and processing equipment to meet the evolving needs of the graphics arts label market. Through several moves and expansions, Adhesives Research grew steadily, developing new capabilities and technologies that enabled the company to address the unmet needs of new markets. Rapid growth led to facility expansions to include the U.S., South America (1980), Europe (1999), and Asia (2000). With headquarters in Glen Rock, Pennsylvania, and Limerick, Ireland, today the company’s facilities span over 250 acres, cover over 300,000+ square feet of development and manufacturing space and employ approximately 300 associates. Today ARx remains an independent company, committed to working with customers as partners in the development of application-specific products that fill their unmet material needs.